DE60132169D1 - Humaner c1 inhibitor hergestellt in der milch transgener säugetiere - Google Patents

Humaner c1 inhibitor hergestellt in der milch transgener säugetiere

Info

Publication number
DE60132169D1
DE60132169D1 DE60132169T DE60132169T DE60132169D1 DE 60132169 D1 DE60132169 D1 DE 60132169D1 DE 60132169 T DE60132169 T DE 60132169T DE 60132169 T DE60132169 T DE 60132169T DE 60132169 D1 DE60132169 D1 DE 60132169D1
Authority
DE
Germany
Prior art keywords
milk
transgener
mammals
human
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60132169T
Other languages
English (en)
Other versions
DE60132169T2 (de
Inventor
Johannes Henricus Nuijens
Veen Henricus Antonius Van
Frank R Pieper
Joris Jan Heus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharming Intellectual Property BV
Original Assignee
Pharming Intellectual Property BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharming Intellectual Property BV filed Critical Pharming Intellectual Property BV
Application granted granted Critical
Publication of DE60132169D1 publication Critical patent/DE60132169D1/de
Publication of DE60132169T2 publication Critical patent/DE60132169T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/107—Rabbit
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C2230/00—Aspects relating to animal feed or genotype
    • A23C2230/05—Milk or milk products from transgenic animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Cardiology (AREA)
  • Environmental Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Dermatology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Animal Husbandry (AREA)
  • Physics & Mathematics (AREA)
DE60132169T 2000-01-31 2001-01-31 Humaner c1 inhibitor hergestellt in der milch transgener säugetiere Expired - Lifetime DE60132169T2 (de)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US17931000P 2000-01-31 2000-01-31
EP00200320 2000-01-31
US179310P 2000-01-31
EP00200320 2000-01-31
US18758000P 2000-03-07 2000-03-07
EP00200810 2000-03-07
US187580P 2000-03-07
EP00200810 2000-03-07
PCT/NL2001/000068 WO2001057079A2 (en) 2000-01-31 2001-01-31 C1 inhibitor produced in the milk of transgenic mammals

Publications (2)

Publication Number Publication Date
DE60132169D1 true DE60132169D1 (de) 2008-02-14
DE60132169T2 DE60132169T2 (de) 2008-12-11

Family

ID=56290105

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60132169T Expired - Lifetime DE60132169T2 (de) 2000-01-31 2001-01-31 Humaner c1 inhibitor hergestellt in der milch transgener säugetiere
DE122011000002C Pending DE122011000002I1 (de) 2000-01-31 2001-01-31 Humaner c1 inhibitor hergestellt in der milch transgener säugetiere

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE122011000002C Pending DE122011000002I1 (de) 2000-01-31 2001-01-31 Humaner c1 inhibitor hergestellt in der milch transgener säugetiere

Country Status (9)

Country Link
EP (1) EP1252184B1 (de)
JP (1) JP2003521914A (de)
AT (1) ATE382635T1 (de)
CA (1) CA2398707C (de)
DE (2) DE60132169T2 (de)
DK (1) DK1252184T3 (de)
ES (1) ES2299473T3 (de)
PT (1) PT1252184E (de)
WO (1) WO2001057079A2 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7067713B2 (en) * 2000-01-31 2006-06-27 Pharming Intellectual Property B.V. C1 Inhibitor produced in the milk of transgenic non-human mammals
DE10112617A1 (de) * 2001-03-14 2002-10-02 Aventis Behring Gmbh Verwendung eines C1-Esterase-Inhibitors zur Verhinderung oder Verzögerung der Abstoßung von Xenotransplantaten in Säugetieren
CA2502539A1 (en) * 2002-10-17 2004-04-29 Pharming Intellectual Property B.V. Protein modification
EP1947116B1 (de) 2003-02-10 2017-06-21 2-BBB Medicines B.V. Differenziell exprimierte Nukleinsäuren der Blut-Hirnschranke bei einer Entzündung
USRE43691E1 (en) 2003-05-16 2012-09-25 Pharming Intellectual Property B.V. C1 inhibitor with short half-life transient treatment
SI2380587T1 (en) 2005-12-21 2018-03-30 Pharming Intellectual Property B.V. Use of a C1 inhibitor to prevent ischemic reperfusion injury
FR2901707B1 (fr) 2006-05-31 2017-09-29 Lab Francais Du Fractionnement Composition de facteur vii recombinant ou transgenique, chaque molecule de facteur vii possedant deux sites de n-glycosylation a motifs glycanniques definis
FR2901796A1 (fr) * 2006-05-31 2007-12-07 Lab Francais Du Fractionnement Procede d'extraction d'une ou de plusieurs proteines presentes dans du lait
PL3028716T3 (pl) 2006-10-10 2021-03-08 Regenesance B.V. Hamowanie układu dopełniacza służące do lepszej regeneracji nerwów
US9738694B2 (en) 2008-06-30 2017-08-22 Cho-A Pharm. Co., Ltd. Gene of porcine alpha-s1 casein, a promoter of the same and use thereof
WO2010087702A1 (en) 2009-01-30 2010-08-05 Stichting Katholieke Universiteit TET2 gene as a marker for diagnosing a myelodysuplastic syndrome (MDS) or an acute myeloid leukemia (AML) and determining the prognosis in a subject
EP2478101A1 (de) 2009-09-16 2012-07-25 Stichting Het Nederlands Kanker Instituut Fra-1-zielgene als wirkstofftargets zur behandlung von krebs
EP2305717A1 (de) 2009-09-21 2011-04-06 Koninklijke Nederlandse Akademie van Wetenschappen Hemmung von TNIK zur Behandlung von Darmkrebs
EP2354245A1 (de) 2010-02-04 2011-08-10 Stichting Top Institute Food and Nutrition MBL2 als Marker für die hepatische PPAR-Aktivität
EP2354244A1 (de) 2010-02-04 2011-08-10 Stichting Top Institute Food and Nutrition MBL2 als Marker für die leberspezifische Insulinresistenz
RU2586774C2 (ru) 2010-08-27 2016-06-10 Пантархей Байосайенс Б.В. Иммунотерапевтический способ лечения рака простаты
EP2465928A1 (de) 2010-12-16 2012-06-20 Academisch Medisch Centrum bij de Universiteit van Amsterdam Behandlung von Th17-vermittelten Krankheiten
CA2876293C (en) 2012-06-27 2023-10-10 Arthrogen B.V. Combination for treating an inflammatory disorder
CN104870475B (zh) 2012-10-25 2019-11-08 美国比奥维拉迪维股份有限公司 抗补体C1s抗体和其用途
CA2889197A1 (en) 2012-11-02 2014-05-08 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof
EP3470837A1 (de) 2013-01-20 2019-04-17 Dyax Corp. Behandlung von pkal-vermittelten erkrankungen
EP2968434B1 (de) 2013-03-15 2017-06-28 Shire Viropharma Incorporated C1-inh-zusammensetzungen zur vorbeugung und behandlung von herditärem angioödem
US10758550B2 (en) 2013-10-04 2020-09-01 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
WO2016080830A2 (en) 2014-11-18 2016-05-26 Pantarhei Bioscience B.V. Immunotherapeutic method for treating pancreatic cancer
PT3280440T (pt) 2015-04-06 2023-02-14 Bioverativ Usa Inc Anticorpos anti-c1s humanizados e métodos de utilização destes
MA43270A (fr) * 2015-11-19 2021-06-02 Takeda Pharmaceuticals Co Inhibiteur de la c1 estérase humaine recombinante et ses utilisations
PL3758739T3 (pl) * 2018-02-28 2024-09-16 Pharming Intellectual Property B.V. Leczenie i zapobieganie stanowi przedrzucawkowemu
WO2019166572A1 (en) 2018-02-28 2019-09-06 Pharming Intellectual Property B.V. Pharmaceutical system for transdermal administration of a c1 -esterase inhibitor
KR20210153097A (ko) 2019-04-16 2021-12-16 다케다 파머수티컬 컴패니 리미티드 기능성 c1 에스테라제 저해제(fc1-inh)의 정량 방법
EP3895726A1 (de) 2020-04-17 2021-10-20 Pharming Intellectual Property BV Verwendung von c1-esterase-inhibitoren zur behandlung von akuter atemnot im zusammenhang mit virusinfektionen
WO2023280981A1 (en) 2021-07-09 2023-01-12 Pharming Intellectual Property B.V. Using c1 esterase inhibitor to treat viral infection-related symptoms

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601034B1 (fr) * 1986-07-03 1989-11-17 Pasteur Institut Inhibiteur de l'activite de la c1-esterase plasmatique (c1-inhibiteur) et d'autres enzymes proteolytiques du groupe des proteases a serine, son procede de preparation, acides nucleiques codant pour cet inhibiteur, methodes de detection d'affections correlees aux defauts dudit inhibiteur a l'aide d'anticorps ou de sondes nucleotidiques et medicaments contenant ledit inhibiteur de synthese
CA2071871A1 (en) * 1989-10-27 1991-04-28 Eric Eldering C1 inhibitor muteins and uses thereof
WO1992022320A1 (en) * 1991-06-14 1992-12-23 Genentech, Inc. C1 inhibitor variants and treating inflammatory response with c1 inhibitor
DE4227762A1 (de) * 1992-08-24 1994-03-03 Behringwerke Ag Verwendung eines Kallikrein-Inhibitors zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie bestimmter Krankheiten
US6713662B1 (en) * 1994-07-27 2004-03-30 Pharming Intellectual Property B.V. Production of collagen in the milk of transgenic mammals
GB9807464D0 (en) * 1998-04-07 1998-06-10 Pharming Bv Purification of human acid µ-glucosidase

Also Published As

Publication number Publication date
CA2398707C (en) 2010-10-26
PT1252184E (pt) 2008-04-15
DE60132169T2 (de) 2008-12-11
CA2398707A1 (en) 2001-08-09
JP2003521914A (ja) 2003-07-22
WO2001057079A2 (en) 2001-08-09
ES2299473T3 (es) 2008-06-01
EP1252184A2 (de) 2002-10-30
ATE382635T1 (de) 2008-01-15
DK1252184T3 (da) 2008-02-04
DE122011000002I1 (de) 2011-05-05
EP1252184B1 (de) 2008-01-02
WO2001057079A3 (en) 2002-08-15

Similar Documents

Publication Publication Date Title
DE60132169D1 (de) Humaner c1 inhibitor hergestellt in der milch transgener säugetiere
TR199903331T2 (xx) Farnesil protein transferas engelleyicileri.
TR199801390T2 (xx) Tromboz tedavisinde kullan�lacak p�ht�la�may� �nleyici maddeler
MX231981B (es) Tratamiento de semillas con combinaciones de piretrinas/piretroides y clotianidina.
DE69937680D1 (de) Agentien zur verbesserung der suesse sowie diese verwendende lebensmittel
WO2001052847A8 (en) Thiazole, imidazole and oxazole compounds and treatments of disorders associated with protein aging
DE60231415D1 (de) Pingpong-verstärker mit automatischem nullen und chopping
SE9904377D0 (sv) Pharmaceutical combinations
DE60122909D1 (de) Behandlung von transgenen maissamen mit clothianidin
DK1001007T3 (da) Sterolkoncentrater , anvendelse og fremstilling deraf
MXPA03003741A (es) Metodos y composiciones para el tratamiento de enfermedades oftalmicas.
EP1441761A4 (de) Verfahren zur prävention und behandlung von infektionen mit dem flavivirus bei tieren
DE69729768D1 (de) Herzschrittmacher mit Bestimmung des anaeroben Schwellwertes
DE69626816D1 (de) Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren
ATE347888T1 (de) Verwendung von aivlosin zur behandlung und prevention der lawsonia-infektionen in schweinen.
DK1133296T3 (da) Ny terapeutisk anvendelse af nicergolin
EE200300213A (et) SARP-1 kasutamine sklerodermia raviks ja/või ennetamiseks
EE200300057A (et) Koostis vähi profülaktikaks ja raviks
TR200002939T2 (tr) Paroksetin maleat
NO20005548L (no) Mykobakterieinhibitorer
TR201900241T4 (tr) Vasoprotektif maddelerin kombinasyonları ve bunları içeren formülasyonlar.
DE69823003D1 (de) Sicherheitsinjektor für medizinische Zwecke
IL143279A0 (en) Novel therapeutic application of low molecular weight heparin
NO20030762L (no) Forbedret spesifisitet i behandling av sykdommer
HK1056828A1 (en) Treatment of burns.